Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.82 |
| ▸ | BLM | P54132 | 4/20 | 0.80 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.77 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.77 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atropine Oxide SCHEMBL162929 | 1.00 | CYP2C19 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL98985 | 1.00 | CYP2C19 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL667605 | 0.99 | CYP2C19 (0.98) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL1490299 | 0.98 | CYP2C19 (0.95) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL1490302 | 0.98 | CYP2C19 (0.95) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL824874 | 0.90 | CHRM2 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL34463463 | 0.90 | CHRM2 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL1321572 | 0.89 | BLM (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL30647266 | 0.89 | BLM (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL29389879 | 0.89 | PABPC1 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629360-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2026-05-19 | — | — | US | claimed |
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | Sydnexis, Inc. | 2025-06-12 | — | — | US | claimed |
| CN-118403054-A | Pharmaceutical composition for controlling and/or reducing myopia progression | 华柏恩视觉研究中心有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-118384160-A | Pharmaceutical composition for controlling and/or reducing myopia progression | 华柏恩视觉研究中心有限公司 | 2024-07-26 | — | — | CN | claimed |
| US-20240165098-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2024-05-23 | — | — | US | claimed |
| US-20240139166-A1 | OPHTHALMIC COMPOSITIONS FOR PRESBYOPIA | Sydnexis, Inc. | 2024-05-02 | — | — | US | claimed |
| US-11896588-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2024-02-13 | — | — | US | claimed |
| US-11890277-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2024-02-06 | — | — | US | claimed |
| US-11883390-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2024-01-30 | — | — | US | claimed |
| EP-4288049-A1 | OPHTHALMIC COMPOSITIONS FOR PRESBYOPIA | Sydnexis, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| US-20220409603-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-12-29 | — | — | US | claimed |
| US-20220409605-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-12-29 | — | — | US | claimed |
| US-20220409604-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-12-29 | — | — | US | claimed |
| US-20220378775-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-12-01 | — | — | US | claimed |
| CN-115279378-A | Ophthalmic compositions comprising D2O | 西德奈克西斯公司 | 2022-11-01 | — | — | CN | claimed |
| EP-4076469-A1 | OPHTHALMIC COMPOSITIONS COMPRISING D2O | Sydnexis, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115192520-A | Ophthalmic composition | 西德奈克西斯公司 | 2022-10-18 | — | — | CN | claimed |
| US-20220265631-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-08-25 | — | — | US | claimed |
| US-20220265632-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-08-25 | — | — | US | claimed |
| WO-2022169959-A1 | OPHTHALMIC COMPOSITIONS FOR PRESBYOPIA | Sydnexis, Inc. (US) | 2022-08-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | CHRM3, CHRM2, CHRM4 | CYP2C19 1937/4885CHRM2 2/4885BLM 456/4885 |
| US-20220409605-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-11896588-B2 | Ophthalmic composition | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-20220265632-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-20220378775-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-11883390-B2 | Ophthalmic composition | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-20220265631-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-20240139166-A1 | OPHTHALMIC COMPOSITIONS FOR PRESBYOPIA | CRYZ, CRYAB, AQP3 | CYP2C19 3173/4885CHRM2 552/4885BLM 71/4885 |
| US-12629360-B2 | Ophthalmic composition | ADRA1D, ADRB2, MYOC | CYP2C19 896/4885CHRM2 8/4885BLM 3034/4885 |
| US-20220409603-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-20220409604-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-11890277-B2 | Ophthalmic composition | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
| US-20240165098-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | CYP2C19 4564/4885CHRM2 271/4885BLM 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.